Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
261-280 of 998 trials

Sepsis-Associated Acute Kidney Injury: TIN816 Treatment Study

We are investigating a new treatment, TIN816, for individuals with sepsis-related kidney injury. The study aims to see if it improves kidney function and overall health compared to a placebo.

Sepsis-Related Acute Kidney Injury≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Acute Myeloid Leukemia: RVU120 with Venetoclax

We are studying a new treatment combining RVU120 and Venetoclax for patients with acute myeloid leukemia who did not respond to earlier therapies. The goal is to assess its safety and effectiveness in improving their condition.

Acute Myeloid Leukemia6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Persistent Atrial Fibrillation: Cryoballoon vs. Medication

We are studying whether early treatment with a cryoballoon is more effective than antiarrhythmic drugs for people with persistent atrial fibrillation. The trial also looks at how these treatments affect quality of life and healthcare needs.

Persistent Symptomatic Atrial Fibrillation>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology

Systemic Sclerosis: Anifrolumab Treatment Study

We are investigating whether Anifrolumab can improve symptoms and lung function in adults with systemic sclerosis. This study compares the new treatment to a placebo to see how well it works.

Systemic SclerosisImmune System DiseasesInterstitial Lung Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

HMB-001 for Glanzmann Thrombasthenia

We are investigating a new treatment to see if it is safe and can help reduce bleeding in people with Glanzmann Thrombasthenia. This study will also look at how the body processes the medication and its effects on quality of life.

Glanzmann's Disease1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematology

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Ketamine for Depression and Alcohol Use Disorder

We are studying whether ketamine can help adults with depression and alcohol use disorder during their addiction treatment. The trial will also look at the safety of this treatment approach.

DepressionAlcohol Use Disorder6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemotePsychiatry

Colorectal Cancer: Reduced Dose Chemotherapy for Older Patients

We are studying whether a lower dose of chemotherapy is as effective as the standard dose for older patients with advanced colorectal cancer. This may help improve quality of life and reduce severe side effects.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Efgartigimod PH20 SC for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will help us understand the right dose and evaluate its safety and effects on daily life.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Chronic Spontaneous Urticaria: Omalizumab Treatment Intervals

We are studying whether adults with well-controlled chronic spontaneous urticaria can safely extend the time between omalizumab treatments while maintaining symptom control.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Methylphenidate for Children with KBG Syndrome

We are studying how well methylphenidate helps children and adolescents with KBG syndrome manage attention and emotional symptoms. This trial also looks at family functioning and any side effects compared to typical ADHD treatments.

KBG Syndrome3-6 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Obesity in Adolescents: Semaglutide Treatment Study

We are exploring whether a weekly injection of semaglutide can help adolescents with obesity lose weight more effectively than a placebo. This study also looks at the safety and overall health impacts of the treatment.

Obesity1-2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Radiprodil for Seizures in Tuberous Sclerosis and Focal Cortical Dysplasia

We are studying the safety and effects of radiprodil on seizures and behavior in patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II. This research may help improve treatment options for these conditions.

Focal Cortical Dysplasia (FCD)Tuberous Sclerosis Complex (TSC)3-6 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology